Meeting
2013 ASCO Annual Meeting
Efficacy and cost of peripheral blood stem cell (PBSC) mobilization with low-dose cyclophosphamide (LD-CY) compared with plerixafor (P) in multiple myeloma (MM) patients (pts) treated with novel induction therapies.
Authors
Lubna Chaudhary
West Virginia University, Morgantown, WV
Lubna Chaudhary , Farrukh Tauseef Awan , Aaron Cumpston , William W. Tse , Michael Craig , Mehdi Hamadani
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Leukemia, Myelodysplasia, and Transplantation
Track
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Sub Track
Autologous Bone Marrow
Citation
J Clin Oncol 31, 2013 (suppl; abstr 7040)
DOI
10.1200/jco.2013.31.15_suppl.7040
Abstract #
7040
Poster Bd #
34H
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Optimizing induction and pretransplant consolidation for myeloma: Results of Myeloma XI, a phase III trial comparing different IMiDs.
First Author: Charlotte Pawlyn
Poster
2013 ASCO Annual Meeting
Results of a phase I/II study (NCT01365559) of carfilzomib (CFZ) replacing bortezomib (BTZ) in BTZ-containing regimens for BTZ-treated patients (pts) with relapsed and refractory multiple myeloma (MM).
First Author: James R. Berenson
Poster
2021 ASCO Annual Meeting
The clinical study of anti-BCMA CAR-T with single-domain antibody as antigen binding domain.
First Author: Lu Han
Poster
2016 ASCO Annual Meeting
MOR202 alone and in combination with pomalidomide or lenalidomide in relapsed or refractory multiple myeloma: Data from clinically relevant cohorts from a phase I/IIa study.
First Author: Marc S. Raab